Where is Biopticon's headquarters?
Biopticon's headquarters is located at 200 Federal Street, Camden.
What is Biopticon's latest funding round?
Biopticon's latest funding round is Unattributed.
How much did Biopticon raise?
Biopticon raised a total of $200K.
Who are the investors of Biopticon?
Investors of Biopticon include Edison Innovation Fund and Rutgers-Camden Business Incubator.
Who are Biopticon's competitors?
Competitors of Biopticon include eSight, Gammex, Exogenesis, Visioneering Technologies, Cutera, Embolx, Cord Blood Registry, ReVision Optics, VidiStar, Clarient and 24 more.
You May Also Like
Cord Blood Registry (CBR) is a newborn stem cell company. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today.
Exogenesis uses atomic scale processing techniques to manufacture medical devices.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
eSight creates electronic glasses that restore or enhance sight for individuals living with vision loss. Worn comfortably like a normal pair of glasses or with prescription lenses built-in, they allow a person with low vision to see in virtually the same manner as someone who is fully-sighted can. The company's SPEX enhances vision for precision tasks, allowing users to pan and zoom the real world or streamed images, and brings critical information to the point of task without overwriting or obstructing natural vision for full situational awareness and mobility.
C2C is a medical device company developing a portfolio of medical devices.
Medical devices for the treatment of severe gastrointestinal disorders
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.